Chapter 7: Blood pressure management in elderly persons with CKD ND  by unknown
Chapter 7: Blood pressure management in elderly
persons with CKD ND
Kidney International Supplements (2012) 2, 377–381; doi:10.1038/kisup.2012.57
INTRODUCTION
This chapter specifically addresses the BP management of
older patients with CKD that is non-dialysis-dependent (i.e.,
CKD ND), many of whom have accumulated co-morbidities
associated with aging, including vascular disease, osteoporo-
sis, and general frailty. The term ‘elderly’ is used for persons
Z65 years of age,354 whereas ‘very elderly’ is reserved for
persons 480 years of age, consistent with the terminology
used in the literature reviewed in this chapter.43,149,355,356 In
using these definitions, we recognize that chronological age
is used as a surrogate for biological age, although this
relationship is highly variable.
The elderly comprise the most rapidly growing proportion
of the population in most parts of the world.357 From 30 to
40 years of age, the GFR generally (but not invariably)
declines, and in the older person, tubular and endocrine
dysfunction in the kidney are common.358,359 Combine this
with the increased prevalence of type 2 diabetes mellitus and
high BP among older persons, it is not surprising that the
elderly constitute the most rapidly growing population of
CKD patients.
In population health surveys, a large proportion of the
elderly have a reduced GFR. In the United States, NHANES
1999–2004 data showed that 37.8% of subjects470 years had
a GFR of o60ml/min/1.73m2 (measured using the MDRD
equation); this prevalence had increased from 27.8% in the
NHANES 1988–1994 data.360,361 Nearly 50% of United States
veterans aged 485 years fulfilled the definition for CKD.362
Similarly in China,363 Australia,364 and Japan,365 a high
prevalence of CKD has been found in older populations.
With greater access to health care among the elderly, this
group is the fastest-growing population requiring dialysis,
with 25% and 21.3% of dialysis patients in the United States
and Australia, respectively, being Z75 years of age366,367 and
between 31 and 36% of patients receiving renal replacement
therapy in different regions of the United Kingdom being
465 years of age.368
7.1: Tailor BP treatment regimens in elderly patients with
CKD ND by carefully considering age, co-morbidities
and other therapies, with gradual escalation of
treatment and close attention to adverse events
related to BP treatment, including electrolyte dis-
orders, acute deterioration in kidney function,
orthostatic hypotension and drug side effects.
(Not Graded)
RATIONALE
The relationships between CKD and BP in the elderly in the
United States have recently been reviewed in detail.369 Among
NHANES III (1988–1994) subjects aged Z60 years of age,
either treated or not treated for a high BP, there was a
J-shaped relationship between BP and CKD prevalence. Thus,
persons with a systolic BP of 120 to 159mmHg or a diastolic
BP of 80 to 99mmHg had the lowest CKD prevalence, with a
higher prevalence associated with a systolic BP o120mmHg
or diastolic BP o80mmHg and a systolic BP Z160mmHg
or a diastolic BP Z100mmHg.361 Analyses of data from
the Kidney Early Evaluation Program (KEEP), as well as
NHANES, indicate that with increasing age, there is an
increase in the prevalence and severity of CKD, confirming the
strong relationship between BP and CKD in the elderly.370,371
Despite these findings, there is little evidence on which to
base recommendations for BP management in elderly
patients with CKD. Systematic assessment of the evidence
base underpinning this Guideline shows that many RCTs
excluded patients 470 years of age. The mean age of
participants rarely exceed 65 years with the upper limit of the
95% CI (i.e., the mean±2 SD) very uncommonly beingZ85
years, meaning no more than about 2.5% of the study
population had an age above this cut-off point (Supplemen-
tary Table 65 online). We therefore cannot draw much direct
evidence from these RCTs to indicate how to properly
manage BP in elderly CKD patients, although some
inferences might be drawn from BP studies in elderly
populations not specifically chosen for the presence of CKD.
Measurement of BP in the elderly. Assessment of BP in the
elderly is made more difficult by such common issues as the
presence of atrial fibrillation (as seen in 25% of patientsZ 70
years in the Chronic Renal Insufficiency Cohort (CRIC)
study372), orthostatic hypotension44,45 and the tendency for
pulse pressure to widen with arterial stiffening, resulting in
systolic hypertension.32,42,373,374
The literature on management of elderly patients has thus
been focused more on systolic than diastolic BP. There is
relevant observational evidence from the SHEP study.374 In
an analysis of 2181 persons 465 years of age in the placebo
arm of this study, systolic BP was more predictive of decline
in kidney function (i.e., rise in SCr by Z0.4mg/dl
[35.4 mmol/l] over 5 years) than diastolic BP, pulse pressure,
or MAP. The mean age was 72 years and patients with ‘renal
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failure’ were excluded. Among those enrolled, the initial SCr
level was 1.04±0.23mg/dl (92±20 mmol/l). Hence, most
subjects probably had normal kidney function or CKD
stages 1–3.
CKD in the elderly. There are clear differences in the causes
of CKD when comparing elderly and younger cohorts.375
Autopsy studies indicate that arteriolar sclerosis, global
glomerulosclerosis, and tubular atrophy are more common
in the elderly, as are renal artery stenosis and cholesterol
embolization.376 Although selection bias is likely, a kidney
biopsy series of 413 patients aged 66 to 79 years and 100
patients aged 80 to 89 years showed nephrosclerosis in 34%
of patients 480 years and in 7% of those 66 to 79 yrs.356
According to registries of kidney failure patients, ‘arterio-
pathic disease’ was the diagnosis in 17 to 38% of patients
commencing dialysis on three continents.375 Although a
discussion as to whether or not nephrosclerosis is an aspect of
kidney aging is beyond the scope of this Guideline, vascular
disease within the kidney is often regarded as a major factor
contributing to decline in kidney function. This predisposi-
tion to vascular disease may influence the response of the
aging kidney to low BP and renin–angiotensin blockade, with
the attendant risks of acute reduction in GFR and
hyperkalemia. This has led to questions regarding the safety
of renin–angiotensin-blocking agents such as ACE-Is and
ARBs in the elderly.377–379
GFR estimation in the elderly. Most equations used to
estimate GFR have been primarily developed in younger
populations, although subgroup analyses show that these
equations perform reasonably well in older people380,381.
Co-morbidities. Co-morbidities are frequently present in
the elderly and may influence BP management. Macrovascular
disease is particularly common. This might influence BP
targets or the preferred agents use to control BP, especially if
heart failure, angina, cerebral vascular insufficiency, or
peripheral vascular diseases are prominent. The presence of
heart failure or cardiomyopathy may lead clinicians to initiate
ACE-Is, ARBs,382 beta-blockers,383 or diuretics independently
of BP treatment. Similarly, angina may be an indication for
beta-blockers or calcium-channel blockers. Hypotension
(orthostatic or persistent) due to BP-lowering treatment
may exacerbate the risk of falls and fractures in the elderly,
especially in patients with co-morbidities such as cerebrovas-
cular disease, osteoporosis, or vitamin D deficiency.
Drugs and the elderly. The pharmacology and pharmaco-
dynamics of BP drugs also change with age, mainly because of
reduced GFR, but also due to changes in hepatic function,
volume of distribution, and other issues that are less well
characterized.384 Side-effect profiles may also vary, either
owing to altered end-organ sensitivity to the drugs, co-
morbidities, or interactions with other medications, such as
diuretics, NSAIDs and COX-2 inhibitors which may accentuate
the adverse kidney effects of renin–angiotensin blockade.384
Goals of BP management in the elderly. It is particularly
important to individualize care in the elderly, bearing co-
morbidities in mind. A philosophy of patient-centered care
(rather than disease-directed care) is particularly relevant as
the elderly become very elderly.385 The high likelihood of
elderly patients developing cardiac and cerebrovascular
complications in the context of a high BP, along with
evidence that kidney function may decline more slowly in the
elderly than in younger patients (particularly when the GFR
is Z45ml/min/1.73m2),386,387 should lead to a greater
emphasis on vascular rather than kidney outcomes. More-
over, particularly in the very elderly, possible beneficial effects
of therapy on morbidity and mortality should be balanced
against any negative effects on quality of life.388
BP TARGETS IN THE ELDERLY
Although there have been many studies of treatment of high
BP in the elderly, there is little evidence specific to the elderly
with known CKD. Most relevant information comes from
observational studies and RCTs involving entire populations
of older hypertensive patients not specifically chosen on the
basis of kidney function (Supplementary Table 66 online).
‘Renal failure’ or a designated upper limit for the SCr
concentration have been an exclusion criterion in many
studies, reducing the applicability of the data to CKD patients.
A meta-analysis of observational studies conducted prior
to 2002, including nearly 1 million subjects selected for having
no previously known vascular disease, indicated that the rates
of stroke, ischemic heart disease, and overall mortality
increased with increasing BP, even among subjects 60 to 89
years of age, although the RR decreased with increasing age.21
RCTs involving elderly patients not selected for having
CKD indicate that it is beneficial to treat high BP in patients
460 years of age. A 2009 Cochrane review of 15 RCTs in
which persons 460 years of age with a systolic BP
Z140mmHg or a diastolic BP Z90mmHg at baseline
received either placebo or a BP-lowering agent indicated that
active treatment reduced total mortality (RR 0.90; 95% CI
0.84–0.97) and total cardiovascular mortality and morbidity
(RR 0.72; 95% CI 0.68–0.77), particularly due to a reduction
in the incidence of stroke.389 Withdrawals due to adverse
events were poorly documented, but in three RCTs that did
report these data, treatment was associated with 111 events/
1000 patient-years, as compared with 65 events/1000 patient-
years with placebo (RR 1.71; 95% CI 1.45–2.00). Although
these findings support treatment of high BP in subjects460
years of age, they do not inform us specifically about patients
with CKD nor about the target BP and they suggest that some
patients will have adverse reactions to drug therapy.
Of concern is that in this Cochrane review,389 when
patients aged Z80 years were specifically considered, there
was no overall reduction in the risk of total mortality with
treatment of BP vs. no treatment (RR 1.01; 95% CI
0.90–1.13), although the reduction in risk of cardiovascular
mortality (RR 0.75; 95% CI 0.65–0.87) was similar to that
seen in patients 60 to 80 years of age. This is in accordance
with a 1999 subgroup meta-analysis of seven RCTs represent-
ing 1670 patients aged Z80 years (who had participated in
trials of anti-hypertensive agents) indicating that treatment
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vs. no treatment was associated with a decrease in the rates of
strokes, major cardiovascular events and heart failure but,
similar to the Cochrane findings, there was no benefit of
treatment in terms of cardiovascular death or overall
mortality.355 Similarly, a 2010 meta-analysis of 8 RCTs
involving treatment of BP in subjects 80 years and older
found that treatment of high BP reduced the risk of stroke,
cardiovascular events and heart failure, but had no effect on
total mortality.390 Meta-regression analysis suggested that
mortality reduction was achieved in the trials with the least
BP reductions and lowest intensity of therapy. These findings
suggest that there might be deleterious effects resulting from
BP treatment in the very elderly undermining the advantages
brought about by the reduced risk of cardiovascular events.
An observational cohort study involving 4071 hyper-
tensive individuals aged 80 years or older (mainly men, since
they were recruited from the Veterans Affairs Administra-
tion) supports this notion.43 All subjects were classified as
‘hypertensive’ according to the International Classification
of Diseases (ICD-9) code, 9.9% as having ‘chronic renal
failure,’ and 84.5% were taking anti-hypertensive medica-
tions. A J-shaped relationship between BP and survival
was seen. Patients with BP o130–139mmHg systolic or
o70–79mmHg diastolic were more likely to die during
5 years of follow-up than those with BP 130–139mmHg
systolic or 70–79mmHg diastolic. With each further
10mmHg decrease in systolic or diastolic BP to
o100mmHg systolic or o50 diastolic the risk increased,
suggesting that overly aggressive BP control might be harmful
in this age group.
A series of retrospective analyses of INVEST has further
highlighted the issue of J-shaped relationships between
systolic BP, diastolic BP and outcomes in elderly hypertensive
patients with CAD.40,42,231 The risk of all cause mortality and
myocardial infarction, but not stroke, increased with
reductions in diastolic BP in the patient group as a whole,
all of whom had CAD and were being treated for high BP.40
In elderly patients included in the study, nadirs of risk
occurred at particular systolic and diastolic BP levels, with
the nadirs generally increasing with age. In patients aged
70 to 80 years, risk increased once systolic BP was less than
135mmHg or diastolic BP o75mmHg, while the risk
increasing when systolic BP waso140mmHg or diastolic BP
o70mmHg in patients Z80 yrs.42 These relationships may
be due to confounding and should not be used to set BP
targets in this population.
In preparing the evidence review for this guideline, the
ERT found four studies involving elderly patients in which
treating to differing targets for BP was part of the study
design (Supplementary Table 67 online).149,389,391–393 The
Shanghai Trial of Nifedipine in the Elderly (STONE) involved
1632 patients aged 60–79 years with a systolic BP
Z160mmHg, or a diastolic BP Z96mmHg, who were
randomized to nifedipine or placebo.392 The mean achieved
BP was 147/85mmHg in the nifedipine group and 156/
92mmHg in the placebo group and although there was no
significant difference in all-cause mortality, there were
reductions in the rates of stroke and severe arrythmia in
the lower-BP nifedipine treated group. Exclusion criteria
included ‘secondary hypertension’ and a blood urea nitrogen
level Z40mg/dl (14.3mmol/l).
The Hypertension in the Very Elderly Trial (HYVET),
involving patients 80 years of age or older, provided further
assurance that BP lowering treatment of very elderly patients
with a sustained BP of Z160mmHg is beneficial.149,391
Aiming to treat to a target BP of systolic o150mmHg and
diastolic o80mmHg in the active-treatment group, the
investigators achieved a BP of 145/79mmHg with indapa-
mide plus perindopril (if needed), compared to 159/
83mmHg with placebo. They demonstrated a reduction in
the rates of all-cause mortality and stroke in the low-BP
active-treatment group over a median 1.8 years of follow-up.
Patients were withdrawn if systolic BP fell to o110mmHg.
However, exclusion criteria included secondary hypertension
(which might be of kidney origin) and a SCr level41.7mg/
dl (4150 mmol/l) (which represents a GFR of 39 or 37ml/
min/1.73m2 for an 80-year-old white man, as estimated by
either the MDRD or CKD Epidemiology Collaboration
(CKD-EPI) equation, respectively and a GFR of 29 or
28ml/min/1.73m2 for an 80-year-old white woman as esti-
mated by the MDRD and CKD-EPI equations, respectively).
The mean baseline creatinine levels were 88.6 mmol/l (1.0mg/
dl) and 89.2 mmol/L (1.0mg/dl) in the active-treatment and
placebo groups, respectively which were well below the
exclusion level. Accordingly, direct extrapolation of these data
to patients with known advanced CKD is not possible.
Although this evidence provides some reassurance regard-
ing treatment of high BP in the very elderly, it only does
so with respect to treatment to a BP target level of
150/80mmHg, and it does not specifically address CKD
patients with a GFR o40 and o30ml/min/1.73m2 for men
and women, respectively. Very importantly, however,
the evidence challenges any tendency toward ‘therapeutic
nihilism’ in the very elderly with high BP and CKD 1–3.
Two Japanese studies failed to show any benefit or harm
from reducing systolic BP to o140mmHg in otherwise
healthy elderly patients.393,394 The Japanese Trial to Assess
Optimal Systolic Blood Pressure in Elderly Hypertensive
Patients (JATOS) aimed to assess optimal systolic BP in
elderly hypertensive patients and randomized 4418 patients
with ‘essential hypertension’ aged 65 to 85 years with a
systolic BP4160mmHg to ‘strict’ BP control (target systolic
BP o140mmHg) or ‘mild’ BP control (target systolic
BP 140–160mmHg).393 Patients with SCr of Z1.5mg/dl
(133 mmol/l) were excluded, as were patients with multiple
co-morbidities. Achieved mean±SD systolic BP was
135.9±11.7mmHg in the strict-control group and
145.6±11.1 in the mild-control group (Po0.001), with
significantly more drugs required in the strict-control group.
There was no difference in cerebrovascular, cardiac, or kidney
end points, nor in total mortality between the two groups at
2 years of follow-up. ‘Renal failure’ occurred in 8 and
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9 patients, respectively. Rates of treatment withdrawal due to
adverse events did not differ between the groups.
The Valsartan in Elderly Isolated Systolic Hypertension
(VALISH) study involved 3260 Japanese participants aged 70
to 84 years, with systolic BPZ160mmHg.394 Like JATOS,393
this study did not demonstrate any differences in outcomes
or adverse events between the strict-control group (systolic
BP goal o140mmHg, achieved mean systolic BP was
136.6mmHg) and the moderate-control group (systolic BP
goal 140–150mmHg, achieved mean systolic BP was
142.0mmHg) after a median follow-up period of 3.07
years.394 Although 43 of the 3260 patients had ‘kidney
insufficiency’ (undefined) at study entry, none had a SCr level
Z2mg/dl (177 mmol/l) since this was an exclusion criterion,
as were many other co-morbidities. Doubling of the SCr, an
increase in the SCr level to 2.0mg/dl (177 mmol/l), or dialysis
occurred in 5 and 2 patients, respectively (non-significant).
The authors concluded that in relatively healthy elderly
Japanese patients, a BPo140mmHg is safely achievable, but
that the trial was underpowered to assess outcome benefits.
No difference was seen between the two groups in terms of
adverse event rates (18.2% with strict control and 17.9% with
mild control, P¼ 0.851).
Thus BP targets in the elderly, with or without CKD,
should be set only after consideration of co-morbidities and
should be achieved gradually. Based on the evidence on BP in
the elderly (not selected for CKD), recent guidelines and
consensus documents generally agree that o140/90mmHg
should be the target in uncomplicated hypertension.117,395,396
The American College of Cardiology Foundation and
American Heart Association (ACCF/AHA), in collaboration
with a large group of other American and European bodies,
acknowledge in their consensus document on hypertension
in the elderly that although ‘there is limited information for
evidence-based guidelines to manage older hypertensive
patients,’ a target of o140/90mmHg is recommended in
uncomplicated hypertension for the age range 65–79 years.395
This document acknowledges that the target for480 years is
unclear, and refers to expert opinion and observational data
(including KDOQI 2002 and JNC 7) suggesting o130/
80mmHg as a target in CKD, irrespective of albuminuria.
From the UK, NICE has published a comprehensive
guideline for management of hypertension in adults which
also recommends BPo140/90mmHg for ‘primary’ hyperten-
sion up to 80 years of age, and for those over 80 years who are
continuing therapy.117 Caution is recommended when starting
BP medications in those over 80 years of age, and no
recommendation is given with respect to the elderly with CKD.
Although intuitively there must be a lower limit for safe
BP control in the elderly and very elderly, there will probably
never be an RCT designed specifically to address this limit in
these populations. We can, however, gain insights from
observations among elderly patients on treatment as outlined
above.42,43 While these date do not allow us to recommend a
lower BP limit on treatment, they do suggest that in the
elderly, it may be prudent not to reduce BP much below the
target BP o140/90mmHg as recommended by ACCF/AHA
and NICE.117,395
In addressing the risks associated with low BP in the
elderly, it is relevant that orthostatic hypotension is more
common than in younger populations, particularly among
those treated for high BP or diabetes and those receiving
sedatives.44,45 As well as causing postural dizziness, low BP is
associated with a higher risk of falls and fractures in elderly
persons in studies that are likely to have included individuals
with and without CKD.9,10,358,397 An additional consideration
when treating elderly CKD patients is that they may differ
from those with well preserved kidney function in terms of
their response to BP lowering agents.
The Work Group decided that it was not possible to
recommend specific BP targets in the elderly with CKD. A
reasonable approach might be to use BP targets as recom-
mended in the younger CKD population (r140/90mmHg
in non-albuminuric CKD and r130/80mmHg in albumi-
nuric CKD as in Chapters 3 and 4), but to reach these targets
gradually, bearing in mind that they may not be achievable
without adverse effects particularly in a patient with multiple
age-related co-morbidities. It is even more difficult to
make recommendations in patients over 80 years of age with
CKD due to the lack of evidence.
With consideration given to the adverse effects of treatment,
the Work Group felt that it was good practice to ask elderly
patients treated for high BP about postural dizziness and to
measure BP immediately (within 1minute) and a few minutes
after standing as well as in the sitting position.44
METHODS FOR BP REDUCTION IN THE ELDERLY
Lifestyle modifications in the elderly, although often
recommended, can compromise quality of life and may
impair nutrition. The place of salt restriction, exercise and
weight control is detailed in the aforementioned ACCF/AHA
document.395 Given that there is very little evidence to
support lifestyle modifications in the treatment of BP in CKD
patients in general, the Work Group decided not to make any
such recommendations in the elderly with CKD. Although
salt restriction might seem to be the most attractive
intervention, it may impact the quality of life, particularly
enjoyment of food. A recent observational study of elderly
persons (Z65 years of age) does not support alcohol
restriction as an intervention to reduce decline in GFR.398
The Work Group felt that drug regimens should be tailored
by carefully considering the elderly patient’s co-morbidities and
any changes in treatment should be very gradual. Close
attention should be paid to potential adverse events related to
BP treatment, including electrolyte disorders, acute deteriora-
tion in kidney function and orthostatic hypotension. Although
many elderly patients with CKD will require several agents,
studies comparing use of various agents in the elderly without
CKD have produced somewhat conflicting results (see Supple-
mentary Tables 66–68 online). The ability of the patient to
adhere to complex poly-pharmacy should be taken into consi-
deration. Some clinicians have expressed concerns about the use
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of drugs that block the renin–angiotensin system in the elderly
with CKD.377–379 This concern is largely due to the perceived
potential for these agents to cause more frequent adverse events
in this population. A recent Cochrane review addressing
pharmacotherapy of all types for treatment of hypertension
in the elderly reported an increased risk of withdrawals due
to adverse effects (RR 1.71; 95% CI 1.45–2.00).389 Since quality
of life is particularly important in the elderly, it may be worth
avoiding drugs that may have negative quality of life
implications, but no clear advice can be given.388,399
Thus given the many differences between the elderly
(particularly the very elderly) with CKD and younger
patients with CKD, it is not possible to recommend any
particular drug class for the reduction of BP in older CKD
patients. However, it is advisable to consider the severity of
CKD, presence of albuminuria, and co-morbidities and their
treatment when prescribing. Therapeutic changes should be
made gradually, with close monitoring for adverse effects due
to low BP or side effects from prescribed agents.
RESEARCH RECOMMENDATIONS
An important NIH funded trial- SPRINT- is currently ongoing
in the United States randomizing patients without diabetes or
significant proteinuria to a systolic BP of o140mmHg or
o120mmHg. Since it contains both elderly patients and
those with CKD, it is likely to provide important evidence to
guide BP management in this subpopulation.171,172
A workshop on kidney disease including the American
Society of Nephrology, the National Institute on Aging, the
American Geriatrics Society, and the National Institute of
Diabetes and Digestive and Kidney Diseases resulted in the
2009 publication of a list of priority areas for research in
kidney disease in the elderly (Table 3).400 Although BP was
not specifically addressed, it highlighted the many areas of
ignorance regarding CKD in the elderly.
Important areas for future research suggested by this
KDIGO Work Group include:
K The effects of different BP targets (e.g., 150/90mmHg vs.
140/90mmHg) in elderly and very elderly patients with
advanced CKD (CKD 3–4) should be assessed by pros-
pective RCTs using a fixed-sequential BP-agent protocol
(e.g., diuretic, ACE-I or ARB, beta-blocker, and calcium-
channel blocker) excluding only patients with angina or
cardiomyopathy.
K The effect of various combinations of agents in the elderly
and very elderly populations should be examined.
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Table 3 | Questions for future research
Mechanisms and biology
Is CKD in elderly people the same condition as CKD in young adults?
How do age-related mechanisms such as fibrosis and cellular
senescence interact with mechanisms underlying CKD progression?
How much risk for CKD progression is determined by age versus factors
such as AKI?
How does fibrosis versus vessel dropout change with age?
Do age- and CKD-associated changes in vascular biology differ from
other parenchymal kidney disease changes associated with age?
Measurement and prognosis
Are there better ways to estimate GFR in older adults to identify CKD?
What are the morphologic correlates of CKD in elderly people?
Are there other markers that can contribute to assessment of CKD
prognosis in elderly people, beyond GFR and cystatin?
CVD
How do age-related changes in vascular biology contribute to CKD-
associated increases in cardiovascular risk?
What are the age-related changes in non-traditional cardiovascular risk
factors in patients with CKD?
Other comorbidities
How do comorbidities differ during the transition from CKD to kidney
failure and need for dialysis?
Can the deterioration in physical functioning and subsequent frailty in
patients with CKD be prevented by physical activity interventions?
How does age interact with exercise in prevention or reduction of
comorbidities associated with CKD progression?
What is the natural history of cognitive impairment associated with CKD
progression, and what happens to cognitive function with the start of
dialysis?
What mechanisms link CKD with cognitive impairment in elderly people?
Are there any interventions to attenuate the development of cognitive
impairment in patients with CKD?
How does preclinical kidney disease relate to other prefrailty risk
factors?
Management and care
How can geriatricians, internists, general family practitioners, and
nephrologists work together to optimize the care of elderly patients
with CKD and kidney failure?
Can age-related declines in kidney function and progression to CKD be
modulated?
AKI, acute kidney injury; CKD chronic kidney disease; GFR, glomerular filtration rate.
Adapted from Anderson S, Halter JB, Hazzard WR et al. Prediction, progression, and
outcomes of chronic kidney disease in older adults. J Am Soc Nephrol 2009;
20: 1199–209 with permission from American Society of Nephrology400 conveyed
through Copyright Clearance Center, Inc.; accessed http://jasn.asnjournals.org/
content/20/6/1199.long.
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